Top

Published in:

01-12-2009 | Clinical trial

Reporting of race and ethnicity in breast cancer research: room for improvement

Authors: Kelly W. Mitchell, Lisa A. Carey, Jeffrey Peppercorn

Published in: Breast Cancer Research and Treatment | Issue 3/2009

Abstract

Health disparities in breast cancer outcomes according to race/ethnicity are well documented. Randomized clinical trials (RCT) offer an opportunity to evaluate differences in disease biology and response to therapy that may contribute to disparities. We conducted a PubMed search to identify all English language original reports of breast cancer RCT from October 2001 to October 2006. The primary outcomes of interest were reporting of accrual and results by race or ethnicity of trial subjects. We evaluated the correlation between study characteristics and reporting of race/ethnicity. A total of 197 eligible trials were identified among 29 journals. Accrual was reported by race in 17% of studies and results analyzed by race in only 2%. Reporting of race was associated with National Cancer Institute funding (38 vs. 13%, P = 0.001), US cooperative group trials (52 vs. 13%, P < 0.0001), trials with US sites (43 vs. 5%, P < 0.0001), and trials enrolling > 500 subjects (24 vs. 12%, P = 0.055). Pharmaceutical industry funding, # of centers, stage of disease, nature of experimental intervention and study outcomes were not associated with reporting of race. Among US studies reporting trial accrual by race/ethnicity, the mean accrual distribution was 81% white, 7.6% black, 9.6% Asian, and 7.2% Hispanic subjects. The majority of breast cancer RCT fail to report the race/ethnicity of participants. Low accrual of black subjects and failure to report accrual and outcomes by race in RCT may contribute to difficulty in understanding and overcoming health disparities in breast cancer.

Ries LAG, Harkins D, Krapcho M, et al. (eds) SEER Cancer Statistics Review, 1975–2003. http://seer.cancer.gov/csr/1975_2003

Curtis E, Quale C, Haggstrom D, Smith-Bindman R (2008) Racial and ethnic differences in breast cancer survival: how much is explained by screening, tumor severity, biology, treatment, comorbidities, and demographics? Cancer 112(1):171–180. doi:10.1002/cncr.23131 CrossRefPubMed

Eley JW, Hill HA, Chen VW, Austin DF, Wesley MN, Muss HB, Greenberg RS, Coates RJ, Correa P, Redmond CK et al (1994) Racial differences in survival from breast cancer. Results of the National Cancer Institute Black/White cancer survival study. JAMA 272(12):947–954. doi:10.1001/jama.272.12.947 CrossRefPubMed

Newman LA, Griffith KA, Jatoi I, Simon MS, Crowe JP, Colditz GA (2006) Meta-analysis of survival in African American and white American patients with breast cancer: ethnicity compared with socioeconomic status. J Clin Oncol 24(9):1342–1349. doi:10.1200/JCO.2005.03.3472 CrossRefPubMed

Bach PB, Schrag D, Brawley OW, Galaznik A, Yakren S, Begg CB (2002) Survival of blacks and whites after a cancer diagnosis. JAMA 287(16):2106–2113. doi:10.1001/jama.287.16.2106 CrossRefPubMed

Ghafoor A, Jemal A, Ward E, Cokkinides V, Smith R, Thun M (2003) Trends in breast cancer by race and ethnicity. CA Cancer J Clin 53(6):342–355. doi:10.3322/canjclin.53.6.342 CrossRefPubMed

Li CI, Malone KE, Daling JR (2003) Differences in breast cancer stage, treatment, and survival by race and ethnicity. Arch Intern Med 163(1):49–56. doi:10.1001/archinte.163.1.49 CrossRefPubMed

Bickell NA, Wang JJ, Oluwole S, Schrag D, Godfrey H, Hiotis K, Mendez J, Guth AA (2006) Missed opportunities: racial disparities in adjuvant breast cancer treatment. J Clin Oncol 24(9):1357–1362. doi:10.1200/JCO.2005.04.5799 CrossRefPubMed

Tammemagi CM, Nerenz D, Neslund-Dudas C, Feldkamp C, Nathanson D (2005) Comorbidity and survival disparities among black and white patients with breast cancer. JAMA 294(14):1765–1772. doi:10.1001/jama.294.14.1765 CrossRefPubMed

10.

Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S et al (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295(21):2492–2502. doi:10.1001/jama.295.21.2492 CrossRefPubMed

11.

Hahn KM, Bondy ML, Selvan M, Lund MJ, Liff JM, Flagg EW, Brinton LA, Porter P, Eley JW, Coates RJ (2007) Factors associated with advanced disease stage at diagnosis in a population-based study of patients with newly diagnosed breast cancer. Am J Epidemiol 166(9):1035–1044. doi:10.1093/aje/kwm177 CrossRefPubMed

12.

Moy B, Tu D, Pater JL, Ingle JN, Shepherd LE, Whelan TJ, Goss PE (2006) Clinical outcomes of ethnic minority women in MA.17: a trial of letrozole after 5 years of tamoxifen in postmenopausal women with early stage breast cancer. Ann Oncol 17(11):1637–1643. doi:10.1093/annonc/mdl177 CrossRefPubMed

13.

Polite BN, Cirrincione C, Fleming GF, Berry DA, Seidman A, Muss H, Norton L, Shapiro C, Bakri K, Marcom K et al (2008) Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840–Cancer and Leukemia Group B. J Clin Oncol 26(16):2659–2665. doi:10.1200/JCO.2007.13.9782 CrossRefPubMed

14.

Revitalization Act NIH In: PL 103-43. 1993

15.

Peppercorn J, Blood E, Winer E, Partridge A (2007) Association between pharmaceutical involvement and outcomes in breast cancer clinical trials. Cancer 109(7):1239–1246. doi:10.1002/cncr.22528 CrossRefPubMed

16.

Arpino G, Nair Krishnan M, Doval Dinesh C, Bardou VJ, Clark GM, Elledge RM (2003) Idoxifene versus tamoxifen: a randomized comparison in postmenopausal patients with metastatic breast cancer. Ann Oncol 14(2):233–241. doi:10.1093/annonc/mdg097 CrossRefPubMed

17.

Williams DR, Lavizzo-Mourey R, Warren RC (1994) The concept of race and health status in America. Public Health Rep 109(1):26–41PubMed

18.

Goetz MP, Knox SK, Suman VJ, Rae JM, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL et al (2007) The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 101(1):113–121. doi:10.1007/s10549-006-9428-0 CrossRefPubMed

19.

Lea RA, Roberts RL, Green MR, Kennedy MA, Chambers GK (2008) Allele frequency differences of cytochrome P450 polymorphisms in a sample of New Zealand Maori. N Z Med J 121(1272):33–37PubMed

20.

Ma CX, Adjei AA, Salavaggione OE, Coronel J, Pelleymounter L, Wang L, Eckloff BW, Schaid D, Wieben ED, Weinshilboum RM (2005) Human aromatase: gene resequencing and functional genomics. Cancer Res 65(23):11071–11082. doi:10.1158/0008-5472.CAN-05-1218 CrossRefPubMed

21.

Swanson GM, Bailar JC 3rd (2002) Selection and description of cancer clinical trials participants–science or happenstance? Cancer 95(5):950–959. doi:10.1002/cncr.10785 CrossRefPubMed

22.

Tejeda HA, Green SB, Trimble EL, Ford L, High JL, Ungerleider RS, Friedman MA, Brawley OW (1996) Representation of African-Americans, Hispanics, and whites in National Cancer Institute cancer treatment trials. J Natl Cancer Inst 88(12):812–816. doi:10.1093/jnci/88.12.812 CrossRefPubMed

23.

Murthy VH, Krumholz HM, Gross CP (2004) Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 291(22):2720–2726. doi:10.1001/jama.291.22.2720 CrossRefPubMed

24.

US Cancer Statistics Working Group United States Cancer Statistics: 1999–2005 Incidence and Mortality Web-based Report. Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2009. Available at: www.cdc.gov/uscs

25.

NIH Policy and Guidelines on The Inclusion of Women and Minorities as Subjects in Clinical Research – Amended, October, 2001. Available via the internet: http://grants.nih.gov/grants/funding/women_min/guidelines_amended_10_2001.htm; Accessed 7 May 2008

26.

Albain K, Unger J, Hutchins L et al. Outcome of African Amercans on Southwest Oncology Group (SWOG) breast cancer adjuvant therapy trials. In: San Antonio Breast Cancer Symposium San Antonio, TX 2003

27.

Woodward WA, Huang EH, McNeese MD, Perkins GH, Tucker SL, Strom EA, Middleton L, Hahn K, Hortobagyi GN, Buchholz TA (2006) African–American race is associated with a poorer overall survival rate for breast cancer patients treated with mastectomy and doxorubicin-based chemotherapy. Cancer 107(11):2662–2668. doi:10.1002/cncr.22281 CrossRefPubMed

28.

Markman M, Petersen J, Montgomery R (2008) An examination of the influence of patient race and ethnicity on expressed interest in learning about cancer clinical trials. J Cancer Res Clin Oncol 134(1):115–118. doi:10.1007/s00432-007-0263-4 CrossRefPubMed

29.

McCaskill-Stevens W, McKinney MM, Whitman CG, Minasian LM (2005) Increasing minority participation in cancer clinical trials: the minority-based community clinical oncology program experience. J Clin Oncol 23(22):5247–5254. doi:10.1200/JCO.2005.22.236 CrossRefPubMed

Title: Reporting of race and ethnicity in breast cancer research: room for improvement
Authors: Kelly W. Mitchell
Lisa A. Carey
Jeffrey Peppercorn
Publication date: 01-12-2009
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 3/2009
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-009-0411-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2009

Caution regarding genotyping methodology for a tri-allelic polymorphism in the novel breast cancer susceptibility gene NQO2

Immunohistochemical validation of multiple phospho-specific epitopes for estrogen receptor α (ERα) in tissue microarrays of ERα positive human breast carcinomas

Opposite effects of protein kinase C beta1 (PKCβ1) and PKCε in the metastatic potential of a breast cancer murine model

STK15 F31I polymorphism is associated with breast cancer risk: a meta-analysis involving 25,014 subjects

A high-resolution integrated analysis of genetic and expression profiles of breast cancer cell lines

The immunohistochemically “ER-negative, PR-negative, HER2-negative, CK5/6-negative, and HER1-negative” subgroup is not a surrogate for the normal-like subtype in breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer